Business Description
Boundless Bio is a San Diego-based clinical-stage company focused on developing new cancer treatments that target extrachromosomal DNA, a key driver of tumor growth in certain cancers. Its lead drug candidate, BBI-940, is currently being tested in Phase 1/2 clinical trials for patients with specific types of breast cancer. The company was founded in 2018 and was previously known as Pretzel Therapeutics before rebranding in July 2019.
